Background Adjuvant treatment with radioactive iodine (RAI) is often considered in the
treatment of well-differentiated thyroid carcinoma (WDTC). We explored the recollections of …

Purpose Despite having a generally favorable prognosis, differentiated thyroid cancer is
known to have a significant, long-term impact on the quality of life of survivors. We wished to …

Post‐operative management of differentiated thyroid cancer (DTC) often involves
administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth
most common cancer in women. DTC therapy requires a multimodal approach, including …

Objective To explore physician recommendations regarding radioiodine remnant ablation
(RRA) as adjuvant treatment in early-stage well-differentiated thyroid carcinoma (WDTC) …

Background: Radioactive iodine (RAI) is widely used in the management of differentiated
thyroid cancer (DTC). The impact of the time interval between total thyroidectomy (TT) and …

Background: The number of thyroid cancer (TC) survivors is increasing exponentially
worldwide. However, little research details the unmet information, support needs, and …

Background: The goal of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is to
treat metastasis and reduce recurrence risk. International guidelines provide broad risk …

Background To the authors' knowledge, the indications for radioactive iodine (RAI) therapy
in patients with differentiated thyroid carcinoma (DTC) are unclear; treatment decisions are …